Seelos Therapeutics Receives Positive EMA Opinion on Orphan Drug Designation for SLS-005 (Trehalose) in Amyotrophic Lateral Sclerosis (ALS)PRNewsWire • 04/20/21
Seelos Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare ConferencePRNewsWire • 04/19/21
Seelos Therapeutics to Participate in the B. Riley Securities' Neuroscience ConferencePRNewsWire • 04/15/21
Seelos Therapeutics Announces a Strategic Device Partnership with AptarGroup, Inc.PRNewsWire • 04/06/21
5 Small-Cap Biotech Stocks Trading Under $10 With Massive Upside Potential24/7 Wall Street • 04/03/21
Seelos Therapeutics Announces Amendment of SLS-002 Agreement to Repurchase a Significant Portion of Royalties for SLS-002 (Intranasal Racemic Ketamine Program)PRNewsWire • 02/18/21
Seelos Therapeutics Announces Issuance of a Patent for Trehalose (SLS-005) in AustraliaPRNewsWire • 01/29/21
Seelos Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter's Option to Purchase Additional SharesPRNewsWire • 01/28/21
Seelos Therapeutics Receives a Notice of Allowance in Japan for SLS-005 (Trehalose)PRNewsWire • 01/22/21
Seelos Therapeutics Announces Dosing of the First Patients in a Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive DisorderPRNewsWire • 01/15/21
Seelos Therapeutics Announces Issuance of a Patent for Trehalose (SLS-005) in IsraelPRNewsWire • 12/21/20
Seelos Therapeutics Raises $10 Million In Private Placement of Senior Secured Convertible NotePRNewsWire • 12/14/20
Seelos Therapeutics to Participate in the 3rd International Conference on Sanfilippo Syndrome and Related DiseasesPRNewsWire • 11/09/20
Seelos Therapeutics Announces Closing of $7.0 Million Registered Direct OfferingPRNewsWire • 09/09/20
Seelos Therapeutics Announces Pricing of $7.0 Million Registered Direct OfferingPRNewsWire • 09/04/20